Program
Dexamethasone
Also written as “dexamethasone”, “OTO-104” and “Dexycu”.
Its studies are mostly in Multiple Myeloma · Cataract · Macular Edema · Meniere Disease · Conjunctivitis, Allergic, led by 30 companies.
Drug pageDexamethasone: every studyMany companies study it; this page follows only the 92 they lead. All 1,797 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 200 open or running | phase 3since Mar 6, 2003 | Mar 6, 2003 | none ahead |
| Ocular Therapeutixits history only | 100 open or running | phase 3since Jan 9, 2014 | Jan 9, 2014 | none ahead |
| Takedaits history only | 100 open or running | phase 4since May 30, 2017 | Jul 25, 2007 | none ahead |
| Oculisits history only | 50 open or running | phase 3since Sep 2, 2021 | Oct 16, 2019 | none ahead |
| Sun Pharmaceutical Industriesits history only | 50 open or running | phase 3since Dec 19, 2007 | Dec 19, 2007 | none ahead |
| Oncotherapeuticsits history only | 40 open or running | phase 2since Aug 26, 2008 | Aug 26, 2008 | none ahead |
| EyePoint Pharmaceuticalsits history only | 30 open or running | phase 4since Dec 13, 2021 | Dec 13, 2021 | none ahead |
| Hamad Medicalits history only | 32 open or running | phase 3since Nov 30, 2020 | Jan 12, 2010 | none ahead |
| Sanofiits history only | 33 open or running | phase 2since Oct 20, 2020 | Oct 20, 2020 | Apr 1, 2027phase 2 · NCT06356571 |
| Alconits history only | 20 open or running | phase 4since Feb 29, 2008 | Feb 29, 2008 | none ahead |
| Azidus Brasilits history only | 20 open or running | phase 3since Apr 8, 2010 | Apr 8, 2010 | none ahead |
| iDropits history only | 20 open or running | phase 2since Sep 26, 2018 | Sep 26, 2018 | none ahead |
| Merckits history only | 20 open or running | phase 4since May 27, 2008 | Mar 17, 2008 | none ahead |
| NTC srlits history only | 20 open or running | phase 3since Nov 9, 2018 | Nov 6, 2018 | none ahead |
| Ocumension Therapeutics (Shanghai)its history only | 20 open or running | phase 4since Jun 20, 2024 | May 11, 2024 | none ahead |
| Quince Therapeuticsits history only | 20 open or running | phase 3since Jan 5, 2011 | Dec 3, 2010 | none ahead |
| Sanwa Kagaku Kenkyushoits history only | 20 open or running | phase 2since Mar 27, 2006 | Mar 27, 2006 | none ahead |
| Ascension Healthits history only | 10 open or running | phase 4since Aug 23, 2018 | Aug 23, 2018 | none ahead |
| Aurobindo Pharmaits history only | 10 open or running | phase 2since Sep 1, 2005 | Sep 1, 2005 | none ahead |
| Bunker Industria Farmaceutica Ltda.its history only | 10 open or running | phase 3since Jul 22, 2009 | Jul 22, 2009 | none ahead |
| Clinical Service, Chinaits history only | 10 open or running | phase 2since Mar 29, 2011 | Mar 29, 2011 | none ahead |
| Cochlearits history only | 11 open or running | no phasesince Sep 12, 2024 | Sep 12, 2024 | none ahead |
| Criteriumits history only | 10 open or running | phase 1since Aug 7, 2012 | Aug 7, 2012 | none ahead |
| Enceladus Pharmaceuticals BVits history only | 10 open or running | phase 2since Jan 3, 2017 | Jan 3, 2017 | none ahead |
| ICON Bioscienceits history only | 10 open or running | phase 3since Sep 9, 2015 | Sep 9, 2015 | none ahead |
| Laboratorios Sophia S.A de C.V.its history only | 11 open or running | phase 3since Jul 30, 2025 | Jul 30, 2025 | none ahead |
| Par Healthits history only | 10 open or running | phase 3since Jul 25, 2013 | Jul 25, 2013 | none ahead |
| Research Insightits history only | 10 open or running | phase 4since Apr 2, 2021 | Apr 2, 2021 | none ahead |
| Simcere Pharmaceutical Groupits history only | 10 open or running | phase 3since Sep 24, 2016 | Sep 24, 2016 | none ahead |
| Travanti Pharmaits history only | 10 open or running | phase 1since May 6, 2009 | May 6, 2009 | none ahead |
Also a collaborator on its studies: Karyopharm Therapeutics, AbbVie, Onyx Therapeutics, Abbott, Tigermed Consulting, Accelovance, ORA, Johnson & Johnson, Hoffmann-La Roche, Amgen, Novum Pharmaceutical Research Services, Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA and Prologue Research International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bristol-Myers Squibb only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Mar 6, 2003.
- May 14, 2007Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT00474188 · 26 enrolled · United States, Australia, Canada
- May 23, 2007Phase 3 study in RecurrenceNCT00478777 · 150 enrolled · Germany
- Nov 6, 20072 phase 1 studies in Multiple MyelomaNCT00555100, NCT00560352
- Jun 2, 2008Phase 3 study in Multiple MyelomaNCT00689936 · 1,623 enrolled · United States, Australia, Austria and more
- Jun 9, 2009Phase 3 study in Multiple MyelomaNCT00928486 · 25 enrolled · Japan
- Nov 8, 2010Phase 3 study in LymphomaNCT01239797 · 646 enrolled · United States, Australia, Austria and more
- Apr 10, 2012Phase 1 study in Multiple MyelomaNCT01575925 · 25 enrolled · United States, Canada
- May 4, 2012Phase 2 study in Multiple MyelomaNCT01593410 · 194 enrolled · China
- Oct 1, 2012Phase 2 study in Multiple MyelomaNCT01698801 · 26 enrolled · Japan
- Jun 28, 2013Phase 3 study in Newly Diagnosed, Previously Untreated Multiple MyelomaNCT01891643 · 23 enrolled · United States, Greece, Italy and more
- Sep 17, 2013Phase 2 study in Multiple MyelomaNCT01946477 · 186 enrolled · United States, Canada, Japan and more
- Dec 10, 20132 phase 2 studies in Multiple MyelomaNCT02011113, NCT02045017
- Jan 23, 2015Phase 2 study in Multiple MyelomaNCT02348528 · 65 enrolled · China
- Aug 16, 2018Phase 3 study in Multiple MyelomaNCT03651128 · 386 enrolled · United States, Belgium, Canada and more
- Aug 6, 2023Named dexamethasoneINNProposed as its International Nonproprietary Name in WHO's List 129 · before, OTO-104
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | Research Insight | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
| Triamcinolone Acetoniderule | clearside-biomedical-inc | phase 3 | 20 |
Studies
All 20 Bristol-Myers Squibb leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03651128Multiple Myeloma · United States, Belgium, Canada and more | 3 | Completed | Apr 13, 2026 | 386 |
| NCT02348528Multiple Myeloma · China | 2 | Completed | Sep 29, 2016 | 65 |
| NCT02045017Multiple Myeloma · Austria, France, Germany and more | 2 | Completed | Jan 27, 2017 | 81 |
| NCT02011113Multiple Myeloma · Japan | 2 | Completed | Sep 2014 | 36 |
| NCT01946477Multiple Myeloma · United States, Canada, Japan and more | 2 | Completed | Apr 30, 2025 | 186 |
| NCT01891643Newly Diagnosed, Previously Untreated Multiple Myeloma · United States, Greece, Italy and more | 3 | Terminated | Jun 25, 2020 | 23 |
| NCT01698801Multiple Myeloma · Japan | 2 | Completed | Nov 26, 2013 | 26 |
| NCT01593410Multiple Myeloma · China | 2 | Completed | Jan 3, 2013 | 194 |
| NCT01575925Multiple Myeloma · United States, Canada | 1 | Completed | Aug 7, 2018 | 25 |
| NCT01239797Lymphoma · United States, Australia, Austria and more | 3 | Completed | Sep 2, 2014 | 646 |
| NCT00928486Multiple Myeloma · Japan | 3 | Completed | Sep 10, 2010 | 25 |
| NCT00689936Multiple Myeloma · United States, Australia, Austria and more | 3 | Completed | Jul 14, 2016 | 1,623 |
| NCT00560352Multiple Myeloma · United States, France, Italy and more | 1 | Terminated | Feb 2011 | 16 |
| NCT00555100Multiple Myeloma · Japan | 1 | Completed | Dec 1, 2010 | 15 |
| NCT00478777Recurrence · Germany | 3 | Completed | Nov 2007 | 150 |
| NCT00474188Lymphoma, Large B-Cell, Diffuse · United States, Australia, Canada | 2 | Terminated | Dec 2008 | 26 |
| NCT00424047Multiple Myeloma · Australia, Austria, Belgium and more | 3 | Completed | Nov 1, 2005 | 351 |
| NCT00420849Multiple Myeloma · Australia, Austria, Ireland and more | 3 | Completed | Oct 2009 | 587 |
| NCT00179647Multiple Myeloma · United States, Canada | 3 | Completed | Dec 2008 | 1,913 |
| NCT00056160Multiple Myeloma · United States, Canada | 3 | Completed | Nov 1, 2005 | 353 |
How it is read
Names in the registry
- “Dexamethasone”, 94 entries
- “dexamethasone”, 20 entries
- “OTO-104”, 9 entries
- “Dexycu”, 4 entries
- “Dexamethasone Oral”, 3 entries
Codes read as this program: OCS01.
Conditions, from the studies’ own filings
- Multiple Myeloma, 87 studies
- Cataract, 13 studies
- Macular Edema, 12 studies
- Meniere Disease, 8 studies
- Conjunctivitis, Allergic, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.